TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05143931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW
Description: Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW
Description: Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WW
Description: Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WW
Description: Participants assigned to all arms will receive 6 months of coaching (Zoom and/or email/text) and commercially-available weight management program focusing on diet, physical activity and mindset skills.
Study: NCT06450145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: interferon α-2b
Description: Eligible APL patients with arsenic-resistant relapse will enter the run-in period, and the subjects in the run-in phase will be treated with arsenic combined with venetoclax. After the run-in period, the patients were treated with interferon α-2b, arsenic trioxide for injection and venetoclax until the outcome of CR/PR/PD/ death/withdrawal/loss to follow-up occurred. Tumor assessments were performed every 4 to 6 weeks (as determined by the investigator) during trial treatment. Those who achieved CR/PR/PD/ withdrawal were then returned to standard treatment (treatment regimen was determined by the clinician), and those who completed the combination treatment period of the trial entered the survival follow-up period.
Study: NCT05578976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral; Tablet
Study: NCT06421337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BraiN20(R)
Description: SEP monitoring will be carried out using the BraiN20® medical device and appropriate electrodes. SEP of both median nerves will be recorded, transferred, and stored to the internal card for their evaluation. BraiN20® Medical Device provides an automatic reading of the presence and feature of a N20 response both ipsilateral and contralateral (as control) to the cerebral hemisphere affected by the stroke and do not require specific training. Furthermore, the device provides an outcome prediction (percentage of likelihood of having mRS ≤ 2 day 7 and 90 after stroke onset) based on an internal algorithm.~BraiN20® measures one N20 wave per 33 seconds. Scalp electrodes are easily embedded on a headband and the wrist electrodes on a glove.
Study: NCT05295550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Realibility
Description: measurement of the thoracic kyphosis with flexicurve and Smartphone inclinometer app
Study: NCT06468020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Gather.town gaming intervention
Description: The online game-based learning intervention (oGBL): The investigator will develop the oGBL intervention based on Rational Emotive Behavior Therapy (REBT), which consists of 5 sessions and plays a game through the Gather.Town platform.
Study: NCT05711407

Intervention type: GENETIC
Intervention: Gene Polymorphisms of MMP-8
Description: Saliva Samples

Intervention type: GENETIC
Intervention: Gene Polymorphisms of MMP-8
Description: Saliva Samples
Study: NCT06724432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral melatonin
Description: Melatonin treated children receive a single dose of oral melatonin 0.5 mg/kg (for a max 10 mg) in a fixed volume of 5 mL of water , 1 hour before induction of anesthesia for surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in the Control group receive 5 ml of 5% dextrose solution once 1 hour before induction of anesthesia
Study: NCT05431907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allocetra-OTS
Description: Allocetra-OTS is a cell-based therapy consisting of non-HLA matched allogeneic peripheral blood mononuclear cells, derived from a healthy human donor following a leukapheresis procedure, induced to an apoptotic stable state.
Study: NCT06726954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS DLPF cortex protocol
Description: It was planned to apply the dorsolateral prefrontal cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS M1 motor cortex protocol
Description: It was planned to apply the M1 motor cortex daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS Protocol
Description: It was planned to apply the daily for 20 sessions.Along with the daily rTMS session, participants will continue to use the medications in the medical treatment at the same effective dose and no dose changes will be made during the treatment.
Study: NCT06720961

Intervention type: PROCEDURE
Intervention: Collection of surgical specimen
Description: Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.

Intervention type: PROCEDURE
Intervention: Collection of surgical specimen
Description: Specimens of CD patients and non-IBD related patients will be collected during the surgery performed for clinical practice, without other risks for the patients, since we will use only leftover material after pathologist analysis. All of the collected surgical samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.

Intervention type: PROCEDURE
Intervention: Collection of stool sample
Description: One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.

Intervention type: PROCEDURE
Intervention: Collection of stool sample
Description: One week before the surgery to remove the stricture, fecal samples from CD patients belonging to B1, B2, B3 groups will be collected. They will be used for the exploratory objective. All of the collected fecal samples will be used for this project and, for this reason, they will not be conserved after the research period. Any residual samples will be destroyed.
Study: NCT06730958

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Follistatin-like protein 1
Description: Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Follistatin-like protein 1
Description: Serum FSL1 level Test principle The kit uses a double-antibody sandwich enzyme-linked immunosorbent assay(ELISA) to assay the level ofHuman Follistatin Like Protein 1(FSTL1) in samples. Add Follistatin Like Protein 1(FSTL1)to monoclonal antibody.Enzyme well which is pre-coated with Human Follistatin Like Protein1(FSTL1)monoclonal antibody, incubation; then, add Follistatin Like Protein 1(FSTL1)antibodies labeled with biotin, and combined with Streptavidin-HRP to form immune complex; then carry out incubation and washing again to remove the uncombined enzyme. Then add Chromogen Solution A, B, the color of the liquid changes into the blue, And at the effect of acid, the color finally becomes yellow. The chroma of color and the concentration of the Human Substance Follistatin Like Protein 1(FSTL1) of sample were positively correlated.
Study: NCT06728449

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cumin tea
Description: The preparation involved boiling 200 ml of water with 2 grams of cumin seeds. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of ginger. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon Peel Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of lemon peel. Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Tea
Description: The preparation involved boiling 200 ml of water with 2 grams of functional tisane (0.6 g cumin seeds, 0.6 g ginger, and 0.6 g lemon peel) Patients were instructed to consume/ have tea twice a day i.e. in mid-morning and in the evening without sugar respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: A carbohydrate-controlled diet focuses on limiting refined carbohydrates and sugars and total carbohydrate restriction to 50-70gm per major meal.
Study: NCT05492903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
Description: A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
Description: A peer-led and supportive group program (10 weekly sessions) designed to address the needs of HCWs with chronic or elevated pain. The intervention will integrate work-based injury protections with pain education and cognitive-behavioral therapy strategies for pain self-management.
Study: NCT06740240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI-Biotin
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI-Biotin. Tracer doses of 68Ga-FAPI-Biotin will be used to detect tumors by PET/CT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-FAPI/18F-FDG
Description: Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-FAPI or 3.7 MBq (0.1 mCi)/Kg 18F-FDG. Tracer doses of 68Ga-FAPI/18F-FDG will be used to detect tumors by PET/CT.
Study: NCT05539053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine B
Description: paclitaxel +N Acetylcysteine orally long course
Study: NCT05101707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous auricular vagus nerve stimulation
Description: Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
Study: NCT05152095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaccaria seed (Wang Bu Liu Xing) pre-attached to adhesive tape used for auricular acupressure
Description: Apply on auricular acupoints, Shenmen and Occiput, apply pressure for 3 minutes, 5 times per day, at the interval of 2 \~ 3 hours, for 5 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Plain ear adhesive tape
Description: Apply on Shenmen and Occiput without applying pressure for 5 days.
Study: NCT04933058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Pain management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV fentanyl
Description: Pain management
Study: NCT04946864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG2575 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: APG2575 monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: combination APG2575+pablociclib
Study: NCT04784338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual shared medical visit
Description: a shared medical visit done by zoom in a group, 1.5 hours

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional classes
Description: A cooking class done by the teaching kitchen demonstrating cooking skills
Study: NCT05101707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy
Description: Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
Study: NCT05785338

Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior angle of the hard palate
Description: Fetal ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Posterior angle of the hard palate
Description: Fetal ultrasound
Study: NCT05133427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOOsonix system ONE-M
Description: All selected BCC areas will be treated by high intensity focused ultrasound
Study: NCT04920994

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-TAPA block
Description: A high-frequency linear ultrasound probe will be used, probe will be placed on the costochondral angle in the sagittal plane and angled deeply to view the lower aspect of the chondrium in the midline, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced into the lower aspect of the chondrium. The same procedure will be repeated on the contralateral side.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTAP block
Description: A high-frequency linear ultrasound probe will be placed obliquely on the upper abdominal wall, along the subcostal margin near the midline. After identifying the rectus abdominis muscle, the ultrasound probe will be gradually moved laterally along the subcostal margin until the transversus abdominis muscle will be identified lying posterior to the rectus muscle, then using in-plane approach, a 22 Gauge Tuohy needle will be introduced medially and directed towards the transversus abdominis plane until its tip reaches the fascia between the rectus abdominis and the transverse abdominis muscles on entering the neurofascial plane. The same procedure will be repeated on the contralateral side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml 0.25% bupivacaine will be injected after the negative aspiration test.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 20 ml 0.25% bupivacaine will be injected after the negative aspiration test.
Study: NCT03939832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fraction of inspired oxygen level
Description: A fraction of inspired oxygen level during cardiac surgery using cardiopulmonary bypass will be set differently: 0.5 versus 1.0.
Study: NCT05735496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 injection
Description: TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
Study: NCT04921163

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium aluminium phospate (SALP)
Description: 1 pancake daily for 4 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aluminium-free pancake
Description: 1 pancake daily for 4 days, without aluminium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aluminium-free pancake
Description: 1 pancake daily for 4 days, without aluminium
Study: NCT05646550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1 Infusion
Description: Short term (3h) infusion of CC-1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-1 Infusion
Description: Short term (3h) infusion of CC-1
Study: NCT04124367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: 30 ml once daily (+70 ml 0.9% saline)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive brain stimulation
Description: 2 mA/35 cm² for 2x20 minutes, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml once daily 0.9% saline

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham intervention
Description: 0 mA/35 cm² for 2x20 minutes, once daily Run-in phase consisting of ramp-up (10 seconds), stimulation (10 seconds), and ramp-down (10 seconds).
Study: NCT05702944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxybenzamine
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Phenoxybenzamine
Description: Patients in sham comparator group take a phenoxybenzamine at least 2 to 5 weeks before surgery. If blood pressure is more than 130/80 mmHg in the sitting position, the patient will take a more amount of phenoxybenzamine. If blood pressure is less than 90 mmHg in the standing position, the patient will take a less amount of phenoxybenzamine. In active comparator group, there is no drug to be taken.
Study: NCT04440241

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative treatment periimplantitis
Description: Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regenerative treatment periimplantitis
Description: Full thickness buccal and lingual flaps will be performed. After debridement of the defect using hand and ultrasonic instruments and implant surface decontamination using titanium brushes (TiBrush®) and saline Regenerative treatment will be performed only in the intrabony component of type 1 peri-implant defects. Guided bone regeneration using a bone substitute (Bio-oss®) and a resorbable membrane (bio-gide®) will be performed in the intrabony and dehiscenses areas of the defect.~The surgeon will be blinded to the assignment of treatment until it is time to close the flaps.
Study: NCT06335940

Intervention type: OTHER
Intervention: Videoregulation
Description: To encourage the use of video-regulation, several measures will be taken to reinforce its use as much as possible:~* Posters visible to all in the dispatch room.~* Regular mailings to all dispatching physicians.~* On-site presence of interns and the study investigator to help doctors who are not used to video-regulation to get to grips with the computer tool.~* Involvement of ARMs to remind doctors to use video-regulation.
Study: NCT05489588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® VIAFORT Vascular Stent
Description: Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.
Study: NCT05738889

Intervention type: DEVICE
Intervention: Fixed lingual retainers applied with Bis-GMA containing composite
Description: Bonding materials of fixed lingual retainers applied with Bis-GMA containing composite

Intervention type: DEVICE
Intervention: Fixed lingual retainers applied with Bis-GMA-free composite
Description: Bonding materials of fixed lingual retainers applied with Bis-GMA-free composite

Intervention type: DEVICE
Intervention: Vacuum-formed retainers
Description: vacuum-forming machine and vacuum formed plates

Intervention type: DEVICE
Intervention: Hawley retainers
Description: Acrylic based hawley retainers
Study: NCT06532071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]CBP8
Description: Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate Meglumine
Description: Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI
Study: NCT06173843

Intervention type: OTHER
Intervention: PFAS / heavy metal testing, exposures
Description: PFAS / heavy metal concentrations, exposure survey

Intervention type: OTHER
Intervention: PFAS / heavy metal testing, exposures
Description: PFAS / heavy metal concentrations, exposure survey
Study: NCT06488001

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole
Description: Pantoprazole 40mg given the night before surgery, 2 hours prior to surgery, and the evening after surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given the night before surgery, 2 hours prior to surgery, and the evening after surgery.